ÂÜÀòÂÒÂ×

Dylan Marchione is an accomplished biomarker strategy expert with extensive experience in the biotechnology and pharmaceutical industries. Currently serving as Biomarker Strategy Lead at Servier Pharmaceuticals, Dylan oversees biomarker strategy and multiomic analyses for clinical trials in IDH1-mutated hematologic malignancies. Previous roles included leadership positions at LifeMine Therapeutics and Agios Pharmaceuticals, where Dylan established a proteomics platform and supported oncology drug discovery through proteomic analysis. Dylan holds a PhD in Pharmacology from the University of Pennsylvania, where research focused on proteomics and cancer epigenetics. Additionally, Dylan has a CORe Credential of Readiness from Harvard Business School Online, and earlier academic qualifications include a Master’s degree in Cell & Molecular Biology and a Bachelor's degree in Biological Sciences from The University of Alabama.